Ligand Pharmaceuticals Inc (LGND)

 

https://www.ligand.com/

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.  
Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported
by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable,
diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering.  We partner with other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and commercialization) to ultimately generate our revenue.











 

https://www.captisol.com/

Captisol Technology

Captisol® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to maximize safety and optimize interaction to improve the solubility, stability, bioavailability or lessen volatility, irritation, smell or taste.

Captisol® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to maximize safety...

Captisol® is a polyanionic beta-cyclodextrin derivative with a sodium sulfonate salt separated from the lipophilic cavity by a butyl ether spacer group, or sulfobutylether (SBE). Captisol® is not a single chemical species, but comprised of a multitude of polymeric structures of varying degrees of substitution and positional/regional isomers dictated and controlled to a uniform pattern by a patented manufacturing process consistently practiced and improved to control impurities.

The selection of Captisol® and its desirable safety profile and drug solubilization properties was based upon extensive evaluations of the mono, tetra and hepta-substituted dominated compositions. Captisol® is the trade name for Ligand's modified beta-cyclodextrin technology.

Several hundred of pre-clinical and clinical studies have been performed and indicate that Captisol® is safe when administered parenterally or orally and does not exhibit the nephrotoxicity associated with beta-cyclodextrin. Relative to beta-cyclodextrin, Captisol® provides higher interaction characteristics and superior water solubility in excess of 100 grams/100 ml – a 50-fold improvement.

 

---

 

Ligand CEO on how company’s helping find a cure for the Coronavirus      

*** MUST SEE LGND VIDEO!! ***

Goldman Sachs filed a Form 3 on February 3, 2020.  They currently have a 10% ownership of LGND


Form 3:  https://www.otcmarkets.com/filing/html?id=13922156&guid=XzZWU6qJChmB1Eh#OWNERSHIPDOC02112020103223_HTM_F3

 

News Updates

04/02/2020:  https://www.otcmarkets.com/filing/html?id=14052770&guid=zJMWUpInoV2pb3h

 

---

ROCHE CONTINGENT VALUE RIGHTS ($LGNDZ)


So let me try to explain this to you in lame mans terms. Here, look at the market cap, look at the cash in hand, look at the cash in value and look at the income of the LGND.
Of all the big boards that you own or have traded, show me a stock that is relatively what this stock shows on the statistics, none of them will come remotely close to cash
value or book value of this stock, guaranteed. Not to mention the institutional holding on this ticker, the names involved is astonishing to say the least. So now going into LGNDZ,
which is also severely undervalued by at least bare minimum 1000% from here, in all reality this should be trading at par value of 10% what the commons are trading, $7.00,
because this ticker LGNDZ is a CVR and if you don't what CVR is, look it up on Google, I already posted on the board, but if one doesn't read those post, which leads me to believe
anyone with low attention span reads the top 4 or 5, you need to read the stickies and the most important posts with links, this ticker is tied to LGND,
which means if the stock hit 330 dollars and change on or before 2023-2024, this is basically an option that you are making a call that the stock will hit those
numbers on or before or by the expiration date. Bottom Line LGNDZ is tied to LGND and certain events need to happen at certain time frame, meaning acquisitions,
FDA approval, any catalyst that move the commons up to reach that strike point.